Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
Anna Artese, Valentina Svicher, Giosuè Costa, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100721-100721
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 724
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility
Caterina Vicidomini, Valentina Roviello, Giovanni N. Roviello
Molecules (2021) Vol. 26, Iss. 7, pp. 1880-1880
Open Access | Times Cited: 118
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study
Chiara Sepulcri, Chiara Dentone, Małgorzata Mikulska, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 11
Open Access | Times Cited: 85
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Uttpal Anand, Shweta Jakhmola, Omkar Indari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
Nicola Borbone, Gennaro Piccialli, Giovanni N. Roviello, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 986-986
Open Access | Times Cited: 69
Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs
Carla Zannella, Annalisa Chianese, Luciana Palomba, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2060-2060
Open Access | Times Cited: 65
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection
Michele Costanzo, Maria Anna Rachele De Giglio, Giovanni N. Roviello
Current Medicinal Chemistry (2021) Vol. 29, Iss. 1, pp. 4-18
Closed Access | Times Cited: 55
RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models
Geng Qin, Chuanqi Zhao, Yan Liu, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 48
COVID-19 update: The race to therapeutic development
Julianne D. Twomey, Shen Luo, Alexis Q. Dean, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100733-100733
Open Access | Times Cited: 60
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Michele Carbone, John A. Lednicky, Shu‐Yuan Xiao, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 4, pp. 546-571
Open Access | Times Cited: 48
Molecular Modeling Strategies of Cancer Multidrug Resistance
Gözde Yalçın
Drug Resistance Updates (2021) Vol. 59, pp. 100789-100789
Closed Access | Times Cited: 46
Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Hylemariam Mihiretie Mengist, Daniel Mekonnen, Ahmed Mohammed, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 41
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2
Na Chen, Baoge Zhang, Lulu Deng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1371-1389
Open Access | Times Cited: 32
Different Aspects of Emetine’s Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19
Mehdi Valipour
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 6, pp. 387-399
Open Access | Times Cited: 27
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals
Juliane Brun, Edi Dharmana, Michelle L. Hill, et al.
Antiviral Research (2025), pp. 106123-106123
Open Access
Alveolar macrophage endosomal-lysosomal system: potential therapeutic targets for COVID-19
Yungang Lan, Gaili Wang, Zhenzhen Wang, et al.
Animals and zoonoses. (2025)
Open Access
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
İsmail Çeli̇k, Meryem Erol, Zekeriya Düzgün
Molecular Diversity (2021) Vol. 26, Iss. 1, pp. 279-292
Open Access | Times Cited: 38
Molecular Docking and In-Silico Analysis of Natural Biomolecules against Dengue, Ebola, Zika, SARS-CoV-2 Variants of Concern and Monkeypox Virus
Mackingsley Kushan Dassanayake, Teng-Jin Khoo, Chien Hwa Chong, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11131-11131
Open Access | Times Cited: 23
Roles of p53-Mediated Host–Virus Interaction in Coronavirus Infection
Xue Wang, Yi Liu, Kaiyuan Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6371-6371
Open Access | Times Cited: 12
Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets
Isabella Romeo, Francesco Mesiti, Antonio Lupia, et al.
Molecules (2021) Vol. 26, Iss. 3, pp. 632-632
Open Access | Times Cited: 28
Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome
Sean P. Ryder, Brittany R. Morgan, Peren Coskun, et al.
Evolutionary Bioinformatics (2021) Vol. 17
Open Access | Times Cited: 28
Design and synthesis of APN and 3CLpro dual‐target inhibitors based on STSBPT with anticoronavirus activity
Youle Zheng, Feng Jin, Yanbin Song, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 3
Inhibitory effect on SARS‐CoV‐2 infection of neferine by blocking Ca2+‐dependent membrane fusion
Yang Yang, Peng Yang, Cong Huang, et al.
Journal of Medical Virology (2021) Vol. 93, Iss. 10, pp. 5825-5832
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top